Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 3/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.50 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.50 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.50 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 6/20 | 0.41 |
| ▸ | DHPS | P49366 | 2/20 | 0.40 |
| ▸ | DRD1 | P21728 | 3/20 | 0.40 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | TDO2 | P48775 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.39 |
| ▸ | CYP2E1 | P05181 | 5/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 5/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 5/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.38 |
| ▸ | CYP2B6 | P20813 | 4/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20700068 | 1.00 | ADRA2A (0.50) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL29981056 | 1.00 | ADRA2A (0.50) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL20700430 | 1.00 | ADRA2A (0.50) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| Hydrochloric Acid SCHEMBL20700831 | 0.99 | ADRA2A (0.49) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| Hydrochloric Acid SCHEMBL20700112 | 0.99 | ADRA2A (0.49) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| Hydrochloric Acid SCHEMBL20700113 | 0.99 | ADRA2A (0.49) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL20700305 | 0.88 | ADRA1A (0.44) | ADRA2AADRA1AADRA1DADRA1BCYP2A6 | |
| SCHEMBL20718138 | 0.87 | DRD1 (0.53) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL20718036 | 0.87 | DRD1 (0.53) | ADRA2AADRA1AADRA1DADRA1BADRA2B | |
| SCHEMBL20718078 | 0.87 | DRD1 (0.53) | ADRA2AADRA1AADRA1DADRA1BADRA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | claimed |
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2022-11-08 | — | — | US | disclosed |
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| EP-3661929-B1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC (US) | 2021-07-14 | — | — | EP | disclosed |
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2021-04-01 | — | — | US | disclosed |
| US-10780074-B2 | Compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-22 | — | — | US | disclosed |
| US-10780074-B2 | Compounds and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2020-09-22 | — | — | US | disclosed |
| EP-3661929-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2020-06-10 | — | — | EP | disclosed |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2019-02-07 | — | — | US | disclosed |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PGI DRUG DISCOVERY LLC | 2019-02-07 | — | — | US | disclosed |
| WO-2019028165-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-07 | — | — | WO | disclosed |
| WO-2019028165-A1 | ISOCHROMAN COMPOUNDS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093606-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | ADRA2A 1042/4885ADRA1A 1181/4885ADRA1D 1267/4885 |
| US-10780074-B2 | Compounds and uses thereof | PYGB, NLN, MAOB | ADRA2A 1042/4885ADRA1A 1181/4885ADRA1D 1267/4885 |
| US-20190038594-A1 | COMPOUNDS AND USES THEREOF | PYGB, NLN, MAOB | ADRA2A 1042/4885ADRA1A 1181/4885ADRA1D 1267/4885 |
| US-11491133-B2 | Heteroaryl-isochroman compounds and uses thereof | GRIN2C, INA, SDHA | ADRA2A 517/4885ADRA1A 784/4885ADRA1D 886/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.